Search company, investor...
Binx Health company logo

Binx Health

mybinxhealth.com

Founded Year

2005

Stage

Series E | Alive

Total Raised

$203.5M

Last Raised

$104M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+20 points in the past 30 days

About Binx Health

Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.

Headquarters Location

245 First St

Cambridge, Massachusetts, 02142,

United States

646-847-8573

Missing: Binx Health's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Binx Health

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Companies in this market are developing technology to support rapid at-home diagnostic testing.

Binx Health named as Challenger among 8 other companies, including Color, Sherlock Biosciences, and Viome.

Missing: Binx Health's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Binx Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Binx Health in 2 CB Insights research briefs, most recently on Apr 11, 2022.

Expert Collections containing Binx Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Binx Health is included in 7 Expert Collections, including Medical Devices.

M

Medical Devices

11,933 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

3,500 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,356 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

D

Digital Health 150

150 items

The winners of the third annual CB Insights Digital Health 150.

H

Health IT

7,901 items

Binx Health Patents

Binx Health has filed 36 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Analytical chemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/8/2020

8/16/2022

Molecular biology, Medical tests, Barcodes, Biotechnology, Fluid dynamics

Grant

Application Date

5/8/2020

Grant Date

8/16/2022

Title

Related Topics

Molecular biology, Medical tests, Barcodes, Biotechnology, Fluid dynamics

Status

Grant

Latest Binx Health News

Global Molecular Diagnostics for Infectious Disease Market Report 2022 to 2026: Featuring Aureum Diagnostics, Aus Diagnostics, Beckman Coulter Diagnostics and Binx Health Among Others - ResearchAndMarkets.com

Jan 16, 2023

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab may disappear while multiplex takes center stage. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations. Trends like: the rise of rapid testing Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. Market Dynamics

Binx Health Frequently Asked Questions (FAQ)

  • When was Binx Health founded?

    Binx Health was founded in 2005.

  • Where is Binx Health's headquarters?

    Binx Health's headquarters is located at 245 First St, Cambridge.

  • What is Binx Health's latest funding round?

    Binx Health's latest funding round is Series E.

  • How much did Binx Health raise?

    Binx Health raised a total of $203.5M.

  • Who are the investors of Binx Health?

    Investors of Binx Health include Johnson & Johnson Innovation, EQT Life Sciences, Alta Life Sciences, Hildred Capital Partners, OrbiMed Advisors and 17 more.

  • Who are Binx Health's competitors?

    Competitors of Binx Health include Sonic Incytes, Capitainer, Ellume, Turtle Health, 52 North Health, IMMUNOSENS, SpinDiag, Viome, Healthtracka, LetsGetChecked and 110 more.

Compare Binx Health to Competitors

Coyote Bioscience Logo
Coyote Bioscience

Coyote Bioscience is dedicated to the development of portability of point-of-care molecular diagnostics, pathogen detection, and life science tools.

Visby Medical Logo
Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The company’s technology development program culminated in an instrument-free, single-use PCR platform that rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. Visby Medical technology also offers the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. It was founded in 2015 and is based in San Jose, California.

5
52 North Health

52 North Health develops NeutroCheck which is a fully-integrated clinical, AI- and medical device-based system for people living with cancer. It is a point-of-care medical device that can be used by patients outside of the hospital to monitor their risk of neutropenic sepsis, a potentially life-threatening complication of chemotherapy. The company was formerly known as Neutrocheck It was founded in 2018 and is based in Cambridge, U.K.

Ultrasight Logo
Ultrasight

Ultrasight develops an automated ultrasound solution that provides AI-based navigation, analysis, and diagnosis at the point of care.

Module Innovations Logo
Module Innovations

Module Innovations is a low-cost portable point-of-care diagnostic device for microbial infections like Urinary Tract Infections (UTI). The company leverages the strength of nano & bio, to create products in healthcare.

Ricovr Healthcare Logo
Ricovr Healthcare

RICOVR Healthcare is the creator of the XALIVA rapid diagnostics platform that provides high-quality, rapid diagnostics results using a small amount of saliva. The company’s product pipeline includes rapid point-of-care tests for Covid-19, THC & drugs-of-abuse, and infectious diseases. The company's patented biosensor platform uses a small drop of saliva to provide high-quality, cost-effective results in approximately five minutes, enabling employers, healthcare systems, and law enforcement to carry out cost-effective, non- invasive workplace and roadside testing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.